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SUMMARY
Serological, epidemiological and molecular aspects of hepatitis C virus (HCV) infection were evaluated in 183 subjects from
Londrina, Paraná, Brazil, and adjacent areas. Serum samples which tested anti-HCV positive by microparticle enzyme immunoassay
(MEIA) obtained from eight patients with chronic hepatitis C, 48 blood donors, and 127 patients infected with the human
immunodeficiency virus (HIV) were submitted to another enzyme immunoassay (ELISA) and to the polymerase chain reaction
(PCR). About 78.7% of samples were also reactive by ELISA, with the greater proportion (70.8%) of discordant results verified
among blood donors. A similar finding was observed for HCV-RNA detection by PCR, with 111/165 (67.3%) positive samples,
with higher rates among HIV-positive subjects and patients with chronic hepatitis than among blood donors. Sixty-one PCR-
positive samples were submitted to HCV genotyping, with 77.1, 21.3 and 1.6% of the samples identified as types 1, 3 and 2,
respectively. Finally, analysis of some risk factors associated with HCV infection showed that intravenous drug use was the most
common risk factor among HIV/HCV co-infected patients, while blood transfusion was the most important risk factor in the group
without HIV infection. The present study contributed to the knowledge regarding risk factors associated with HCV infection and
the distribution of HCV genotypes in the population evaluated.
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INTRODUCTION
About 170 million people all over the world are infected with
hepatitis C virus (HCV), although many ignore such fact30. In most
cases, the infection develops as an asymptomatic clinical picture but
with severe consequences, since about 80% of the infected subjects
develop chronic hepatitis, cirrhosis or hepatocellular carcinoma16,28.
Co-infection of HCV-infected subjects with the human
immunodeficiency virus (HIV) has important implications for the
prognosis and management of both diseases. These subjects show
elevated alanine aminotransferase levels and are at a higher risk of
developing fibrosis, cirrhosis, liver failure or hepatocellular carcinoma
than subjects infected only with HCV6; in addition, they show a higher
risk of developing hepatic toxicity related to the use of highly active
antiretroviral therapy than patients infected only with HIV5,26.
The use of the polymerase chain reaction (PCR) for the detection of
HCV-RNA allows the identification of the presence of active HCV
infection. However, RNA levels may show fluctuations with non-
detectable periods even in patients not submitted to interferon therapy7.
Patient counseling regarding the risk-benefit of treatment also requires
analysis of a liver biopsy and the determination of the HCV genotype.
Differences in the response to treatment depending on the HCV genotype
have been observed, with type 1 being more resistant than types 2 and
319. Genotyping based on the amplification of the 5’ untranslated region
(5’-UTR) has the advantage that it can be performed on PCR amplification
products obtained from HCV-RNA detection tests7,10.
HCV prevalence varies among different regions of the world or
even among different groups studied. Prevalence is lower in populations
highly selected by previous screening for risk factors associated with
the infection, such as blood donors, and is higher among groups highly
exposed to parenteral transmission of the virus, such as intravenous
drug users or hemodialysis patients2,13,21,29. In Brazil, available data
usually refer to large centers8,12,22. In Londrina, Paraná, data are also
very scarce. PONTELLO et al. (1993) detected 1.2% positivity of anti-
HCV antibodies in blood donors23, and REICHE et al. (2000), studying
1,006 pregnant women assisted at a University Hospital during the
period from 1996-1998, reported 0.8% positivity determined by enzyme
immunoassay (ELISA), with no confirmation of antibody specificity
or determination of the presence of HCV-RNA in seropositive cases24.
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The aim of the present study was to evaluate the serological,
epidemiological and molecular aspects of HCV infection in subjects
living in the Londrina region, Paraná.
MATERIAL AND METHODS
Specimens: We studied 183 samples sent to the Clinical Laboratory
of the University Hospital, Londrina, PR, between December 2001
and September 2002. The samples were selected from patients attending
infectious diseases ambulatories and detected anti-HCV reactive at
routine laboratorial screening. These subjects (48 blood donors and
127 HIV-patients with serological evidence of co-infection with HCV)
were undergoing their first clinical evaluation for hepatitis C after the
anti-HCV reactive result, and their status about HCV infection was
unknown. Other eight patients selected had a confirmed diagnosis of
chronic hepatitis C, and they were previously known to be HCV-RNA
positive, but HCV genotype was not still determined. No patient was
under interferon therapy. The study was approved by the Research Ethics
Committee of the institution and all patients signed a written informed
consent.
Anti-HCV screening: Anti-HCV antibodies were initially detected
by an automated microparticle enzyme immunoassay (MEIA;
AXSYM® HCV version 3.0, Abbott Laboratories, USA), the method
routinely used in that laboratory, and confirmed by a second ELISA
assay (Murex® anti-HCV version 4.0, Murex Biotech-Abbott, South
Africa). Results were expressed as the optical density of the sample
(S) divided by the cut-off value (CO). Samples were considered to be
strongly reactive in one assay when showing a S/CO ratio ≥ 3.0 or ≥
5.0 in ELISA or MEIA, respectively. Samples were classified as weakly
reactive when the S/CO ratio was between 1.0 and 2.9 in ELISA or
between 1.0 and 4.9 in MEIA14,15. Samples with a S/CO ratio < 1.0 in
ELISA or MEIA were considered to be non-reactive.
Detection of HCV-RNA: Samples were stored at -20 ºC and later
submitted to nested-PCR using primers for the amplification of the 5’
untranslated region (5’-UTR) of HCV. The assay was performed on
165 samples; other 18 samples were stored at 4 ºC for several days,
and were not tested by PCR because of possible RNA degradation.
Viral RNA was extracted from 100 µL serum with 300 µL Trizol®
(Gibco-BRL, USA), separated in an aqueous phase by chloroform
addition and precipitated with isopropanol. The pellet was washed in
70% ethanol and dissolved in 12 µL of a solution containing diethyl
pyrocarbonate-treated water and 300 ng of random primers (Pharmacia
Biotech, Sweden)4. After a denaturation step at 70 ºC for 10 min, cDNA
was synthesized from RNA by the addition of a solution containing
100 U reverse transcriptase (SuperScriptTM II RNase H-Reverse
Transcriptase, Gibco-BRL), 50 mM Tris-HCl, 75 mM KCl, 3 mM
MgCl2, 10 µM DTT, 5 U RNase inhibitor, and 0.5 mM deoxynucleoside
triphosphate mix (dNTP), in a final reaction volume of 20 µL. The
mixture was incubated at 42 ºC for 90 min and then heated to 70 ºC for
10 min. A two-round PCR was run in a final reaction volume of 50 µL
using a protocol including an initial cycle at 94 ºC for one min and 40
cycles at 94 ºC for 30 s, 55 ºC for 30 s and 72 ºC for 30 s, followed by
a final extension cycle at 72 ºC for five min. NCR1 (5'-
GTATCTCGAGGCGACACTCCACCATAG-3') and NCR2 (5'-
ATACTCGAGGTGCACGGTCTACGAGAC-3') were used as outer
primers, and NCR3 (5'-CCACCATAGATCTCTCCCCTGT-3') and
NCR4 (5'-CACTCTCGAGCACCCTATCAGGCAGT-3') as inner
primers. For the first amplification, 5 µL of cDNA was mixed with 45
µL of a reaction mixture containing 20 mM Tris-HCl, 50 mM KCl, 2
mM MgCl2, 0.15 mM dNTP mix, 1 U Taq DNA polymerase (Gibco-
BRL), and 12.5 pmol of each outer primer. The second amplification
was performed using 3 µL of the first amplification product and a
mixture of the same composition as described above, but using the
inner primers, 0.2 mM dNTP mix and 1.5 mM MgCl2. The second
PCR amplification product was separated by electrophoresis on 1.5%
agarose gel stained with ethidium bromide and visualized under
ultraviolet light9.
HCV genotyping: Nucleotide sequencing of HCV 5’-UTR was
carried out for 61 PCR-positive samples (seven blood donors, eight
chronic patients and 46 HIV-seropositive subjects). The PCR product
was purified (QIAquick®, QIAGEN, Germany) and submitted to
sequencing (ABI PRISM® Big Dye Terminator Cycle Sequencing
Ready Reaction Kit, PE Applied Biosystems, USA) in an automatic
GeneAmp 9600 thermal cycler using 25 cycles at 96 ºC for 10 s, 50 ºC
for five seconds and 60 ºC for four min. The product was precipitated
with sodium acetate and ethanol, and later dissolved in loading buffer
and submitted to electrophoresis in the ABI PRISM 377 DNA Sequencer
(PE Applied Biosystems). The sequences obtained were edited with
the SEQUENCHER program, aligned using the BIOEDIT program,
and compared with published sequences available at GenBank: 1a
(M62321 and D10749), 1b (D90208), 1c (D14853), 2a (D00944), 2b
(D10998), 3a (D28917), 3b (D49374), 3c (D16612), 4a (Y11604), 5a
(Y13184), and 6a (Y12083).
Risk factors: Subjects with detectable HCV-RNA were asked
regarding possible risk factors, such as the use of intravenous drugs,
blood transfusion and sexual relations with multiple partners (defined
as more than 10 lifetime sexual partners)3.
Statistical analysis: Results were expressed as absolute and relative
frequencies. The kappa coefficient (κ) was used for comparison of the
performance of the different assays17. Proportions were compared by
the chi-square test (χ2). The odds ratio (OR) and 95% confidence
interval (CI) were calculated to determine the association between
variables. The statistical tests were performed using the EPI-INFO
program version 6.04d (CDC, Atlanta, USA), and statistical significance
was assessed at the 0.05 probability level in all analyses (p < 0.05).
RESULTS
Anti-HCV screening: Of 183 anti-HCV-positive samples by
MEIA, 59 (32.2%) were weakly reactive (S/CO ratio between 1.0 and
4.9) and 124 (67.8%) were strongly reactive (S/CO ≥ 5.0). This
reactivity was confirmed in 144 (78.7%) samples by a second screening
assay (ELISA). Positive results by the two screening assays were
observed in 22/59 (37.3%) and 122/124 (98.4%) samples from the
weakly reactive and the strongly reactive groups, respectively. Only
29.2% (14/48) of the blood donor samples tested positive by the two
assays used, in contrast to the 96.1% (122/127) and 100% (8/8)
agreement between these two methods obtained for HIV-positive and
HCV chronic patients, respectively (χ2 = 95.22; p < 0.001).
PCR: HCV-RNA was detected in 111/165 (67.3%) samples
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evaluated. PCR positivity was higher in patients with chronic hepatitis
C (100%; 8/8 samples) and HIV-positive patients (75.6%; 96/127
samples) than in blood donors (23.3%; 7/30 samples) (χ2 = 34.19; p <
0.001). All PCR-positive samples were reactive in both MEIA and
ELISA. A comparison between the MEIA, ELISA and PCR results is
shown in Table 1.
Genotyping: HCV genotype was determined in 61/111 PCR-
positive samples. Genotypes found were type 1 (77.1%), followed by
type 3 (21.3%) and type 2 (1.6%). The most common subtypes were
1a (42.6%), 1b (24.6%) and 3a (19.7%). Differentiation between
subtypes 1a and 1b was not possible in 8.2% of the samples due to the
small variability in the 5’-UTR region. This was observed for the sample
identified as type 2, in which subtypes 2a and 2b could also not be
differentiated. Both subtypes 1c and 3c were also identified in only
one sample (1.6%).
Risk factors: The 111 subjects with detectable HCV-RNA were
asked regarding the possible route of infection. Among the subjects
co-infected with HCV/HIV, 52.1% (50/96) were intravenous drug
users, 14.6% (14/96) had received blood transfusion and 59.4% (57/
96) had sexual relations with multiple partners. Among the subjects
infected with HCV alone, only 6.7% (1/15) were intravenous drug
users, 33.3% (5/15) had received blood transfusion and 20.0% (3/15)
had multiple sexual partners. No risk factors associated with HCV
could be identified in 53.3% and 5.2% of subjects infected with HCV
only or co-infected with HCV/HIV, respectively (Table 2). Subtype
1a was very common among drug users (53.8%; 14/26 samples) and
subjects with multiple sexual partners (48.1%; 13/27 samples), and
subtype 1b was common among recipients of blood transfusion
(45.5%; 5/11 samples).
Table 2
Frequency of risk factors associated with human immunodeficiency virus (HIV) infection among subjects with hepatitis C virus (HCV)-RNA detected by the
polymerase chain reaction (PCR)
HIV (+) HIV (-)1
(n = 96) (n = 15) OR 95% CI p*
Risk factor N2 (%) N2 (%)
Parenteral
Intravenous drug user 50 (52.1) 1 (6.7) 15.22 1.92-120.35 < 0.001
Blood transfusion 14 (14.6) 5 (33.3) 0.34 0.10-1.15 0.131
Sexual
Multiple partners 3 57 (59.4) 3 (20.0) 5.85 1.55-22.09 0.004
Male homosexual 11 (11.5) 0 (0.0) - - -
Drug user partner 4 6 (6.3) 0 (0.0) - - -
Not identified 5 (5.2) 8 (53.3) 0.05 0.01-0.19 < 0.001
1
 blood donors (7) + patients with chronic hepatitis C (8); 2 number of subjects who presented the risk factor; 3 more than 10 lifetime sexual partners; 4 subject who is not
a drug user; OR: odds ratio; CI: confidence interval; *p < 0.05
Table 1
Comparison between the results obtained by microparticle enzyme immunoassay (MEIA), enzyme immunoassay (ELISA), and polymerase chain reaction (PCR) for
183 serum samples initially reactive in MEIA
MEIA ELISA PCR Total
Positive Negative Not done
1 ≤ S/CO < 5b (n = 59) 1 < S/COa 0 23 14 37
1 ≤ S/CO < 3b 1 8 0 9
S/CO ≥ 3c 5 7 1 13
S/CO ≥ 5c (n = 124) 1 < S/COa 0 1 1 2
1 ≤ S/CO < 3b 0 0 0 0
S/CO ≥ 3c 105 15 2 122
                          Total 111 54 18 183
MEIA: microparticle enzyme immunoassay (AXSYM®, Abbott, USA); ELISA: enzyme immunoassay (Murex®, Murex Biotech-Abbott, South Africa); PCR: polymerase
chain reaction; S/CO: ratio of sample optical density divided by the reaction cut-off (interpreted as non-reactivea, weakly reactiveb or strongly reactivec); n: number of
samples; MEIA (weak/strong) x PCR (+/-): κ = 0.682 (p < 0.001); MEIA (weak/strong) x ELISA (+/-): κ = 0.670 (p < 0.001); MEIA (weak/strong) x ELISA (weak/
strong): κ = 0.539 (p < 0.001)
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DISCUSSION
Retesting MEIA reactive samples by a second ELISA showed that
the agreement between the two methods was higher in the chronic
hepatitis C group and HIV-positive subjects than in blood donors. Since
all MEIA and ELISA reactive samples submitted to PCR showed a
positive result, one may suppose that a reactive result by two different
screening tests indicates that the detected antibodies are anti-HCV
specific. The use of a second ELISA for confirmation of anti-HCV-
positive results has first been proposed as an applicable strategy to
reduce the use of supplemental tests in up to 85% of cases found in a
clinical laboratory14.
The level of reactivity in the anti-HCV antibody screening test is
related to the positivity in PCR. A PCR-positive result was observed in
86.8% of samples with a strong reactivity by MEIA, in contrast to
only 13.6% of samples with weak reactivity by MEIA that presented
detectable HCV-RNA. In a similar study, 71% of samples with a S/CO
ratio higher than 3.0 in ELISA and 50% of the samples with a S/CO
ratio between 1.0 and 3.0 tested positive by PCR15. Another study
reported 91.5% positivity in PCR when the S/CO ratio in ELISA was
higher than 3.0 and only 17.6% when the S/CO ratio was between 1.0
and 3.011.
The procedure employed for the determination of the genotype of
the samples evaluated was nucleotide sequencing of 5'-UTR. Although
this is the most conserved region of the HCV genome, it is polymorphic
enough for genotype differentiation of clinical specimens and has the
advantage of using the same PCR amplification product generated in
viremia detection tests, thus reducing laboratory costs. Difficulties in
the differentiation between subtypes 1a and 1b and subtypes 2a and 2b
were observed for some samples. A study comparing sequencing of
the 5'-UTR and NS5 regions showed that 3.4% of strains classified as
1a by 5'-UTR sequencing were 1b when the NS5 region was sequenced,
and 25% of those classified as 1b by 5'-UTR analysis resulted in 1a
when sequencing the NS5 region10. Nevertheless, this fact does not
invalidate the method since for therapeutic purposes determination of
the main types is sufficient1.
In the present study, most samples were identified as HCV genotype
1, with a predominance of subtype 1a followed by subtype 1b. These
results are in agreement with the literature, with genotype 1 being the
most common HCV genotype in North and South America, Europe
and Asia27. In a previous study carried out in a Brazilian population
consisting of different HCV exposure categories, genotype 1 was
detected in 72% of the subjects, type 2 in 2%, type 3 in 25.3%, and
type 4 in 0.7%21. Differences in the distribution profile of the HCV
subtypes in the different geographical regions of Brazil have been
reported, with subtype 1b being the most prevalent in the southeast
area followed by subtype 1a, subtypes 1b and 3a being the most frequent
in the northeast area, and subtype 1a being the most common in the
center-west region, followed by subtype 3a18.
The frequency of risk factors was evaluated in patients with active
infection, evidenced by a PCR-positive result (n = 111). These data
did not differ significantly from that found in all anti-HCV-reactive
subjects (n = 183; data not shown). Nevertheless, the use of HCV-
RNA-positive subjects might allow a better analysis of the results,
with the exclusion of false-positive cases which are very common
among blood donors.
A large number of subjects who admitted to have a sexual risk
behavior or who were intravenous drug users were observed in the
group co-infected with HCV and HIV. This finding agrees with previous
observations made in HIV-seropositive patients from Rio de Janeiro,
Brazil, where at least 70% of the subjects have been demonstrated to
be engaged in high risk sexual activity and 70% of intravenous drug
users were infected with HCV22. In HIV/HCV co-infected patients from
São Paulo, Brazil, intravenous drug use was also the main risk factor
detected20.
The number of subjects in whom the infection source was associated
with blood transfusion was small when compared to those with
intravenous drug use as risk factor. Data reported by the Centers for
Disease Control and Prevention (CDC, USA) indicate blood transfusion
as the main cause of infections acquired more than 10 years ago. The
number of cases associated with intravenous drug use is increasing,
and currently accounts for 60% of HCV transmission in the United
States3.
The number of subjects with unknown source of infection was high,
especially among blood donors and patients with chronic hepatitis C.
In a community-based survey carried out in the State of Mato Grosso,
Brazil, 78.9% of anti-HCV-reactive subjects did not present any evident
risk factor for exposure to the virus, which was attributed to the fact
that the group consisted of healthy subjects who probably could not
remember such an important fact as a blood transfusion during
childhood25. Risk factors related to HCV infection could not be detected
in 5.2% of HIV/HCV co-infected patients, a rate similar to that observed
in São Paulo, where 5.4% of HIV/HCV patients also denied any possible
route of infection20.
Although the serological, epidemiological and molecular aspects
of HCV infection here obtained are related to a small population, this
study was justified by the lack of information about HCV infection in
the Londrina region, Paraná. Thus, it demonstrated the importance to
continue this study in order to establish routine procedures that can be
applied to the screening and confirmation of the diagnosis, as well as
to provide an applied methodology for the epidemiological investigation
of the virologic profile and therapeutic monitoring of HCV-infected
patients.
RESUMO
Aspectos sorológicos, epidemiológicos e moleculares da infecção
pelo vírus da hepatite C na população da região de Londrina,
Paraná, Brasil, 2001-2002
Aspectos sorológicos, epidemiológicos e moleculares da infecção
pelo vírus da hepatite C (HCV) foram avaliados em 183 indivíduos da
região de Londrina, Paraná. Amostras soropositivas para anti-HCV pelo
enzimaimunoensaio de micropartículas (MEIA), provenientes de oito
pacientes com hepatite C crônica, 48 doadores de sangue e 127
indivíduos infectados pelo vírus da imunodeficiência humana (HIV),
foram submetidas ao enzimaimunoensaio (ELISA) e a reação em cadeia
da polimerase (PCR). Em 78,7% das amostras, verificou-se resultado
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reagente no ELISA, ocorrendo maior proporção de resultados
discordantes entre doadores de sangue (70,8%). O mesmo ocorreu com
a pesquisa do RNA viral, na qual 111/165 (67,3%) amostras foram
positivas com PCR, verificando-se maior positividade entre indivíduos
HIV soropositivos e pacientes com hepatite crônica do que em doadores
de sangue. Em 61 amostras com viremia detectável, realizou-se a
genotipagem do HCV, encontrando-se os genótipos 1 (77,1%), 3
(21,3%) e 2 (1,6%). Por fim, foram avaliados os fatores epidemiológicos
em indivíduos com infecção ativa, nos quais o uso de drogas injetáveis
foi o principal fator de risco encontrado em indivíduos co-infectados
pelo HIV/HCV e a transfusão sangüínea foi o mais comum em
indivíduos sem infecção pelo HIV. O presente estudo contribuiu para
o conhecimento do perfil da infecção pelo HCV em indivíduos da nossa
população e da distribuição dos genótipos do HCV nesta região.
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